KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells

KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells

AbstractPaclitaxel (PTX), a tubulin-binding agent, is widely used and has shown good efficacy in the initial period of treatment for non-small cell lung cancer (NSCLC). However, the relatively rapid acquisition of resistance to PTX treatments that is observed in virtually all cases significantly lim...

Full description

Bibliographic Details
Main Authors: Junyi Pu, Jianfeng Shen, Zihua Zhong, Ma Yanling, Jie Gao
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Artificial Cells, Nanomedicine, and Biotechnology
Subjects:
Lung adenocarcinoma
paclitaxel resistance
methylation chip analysis
transcriptome sequencing
KANK1
Molecular target therapy
Online Access:https://www.tandfonline.com/doi/10.1080/21691401.2020.1728287

Internet

https://www.tandfonline.com/doi/10.1080/21691401.2020.1728287

Similar Items